Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Eur J Immunol. 2010 Sep;40(9):2549–2556. doi: 10.1002/eji.201040303

Figure 1. IL-17 levels and IL-17+ cells are increased in estrogen-treated autoimmune lupus mice.

Figure 1

Splenic lymphocytes (5×106/ml) from estrogen-and placebo-treated lupus–prone male NZB/W mice were either (A) cultured in the presence of IL-6+TGFβ+antiCD3 antibodies for 72 hr and IL-17 levels in the culture supernatants were analyzed by ELISA or (B, C) were stimulated with IL-6+TGFβ+antiCD3 antibodies for 21 hrs followed by stimulation with PMA (100 ng/ml), ionomycin (2 µg/ml) and brefeldin A (1 µg/ml) for 3 h and stained for intracellular IL-17 expression. (B) Representative flow cytometry plots of IL-17+ cells (percentages indicated). (C) Mean percentage of IL-17+ cells. (A, C) Means ± SEM (estrogen = 2; placebo = 7); *** p<0.001, Tukey-Kramer multiple comparison test.